Navigation Links
HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Date:1/10/2008

NEW YORK, January 10 /PRNewswire-FirstCall/ -- HealthCare Technologies Ltd., (the "Company") today announced that it received a letter dated January 7, 2008 from the Staff of the Listing Qualifications Department (the "Staff Determination") of The NASDAQ Stock Market LLC, which indicated that because the Staff believes that the Company's Plan of Arrangement with NexGen Biofuels, Inc., which closed on December 31, 2007, constituted a reverse merger, the surviving entity is required to submit an initial listing application and satisfy Nasdaq's initial listing standards. On September 7, 2007, NexGen Biofuels, Ltd. submitted its listing application. However, the application was not approved because, among other things, the Company did not meet the minimum $4 bid price requirement for initial listing. Accordingly, the Company's securities will be delisted from The NASDAQ Stock Market. In that regard, unless the Company requests an appeal of this determination, NASDAQ will suspend trading of the Company's securities on the Capital Market at the opening of business on January 16, 2008.

In response, the Company intends to timely request a hearing before a NASDAQ Listing Qualifications Panel to address the Staff Determination and seek continued listing in accordance with applicable NASDAQ rules. The Company's hearing request will stay any delisting action pending the issuance of a decision by the Panel following the hearing.

In the event that the Company's appeal is unsuccessful, the Company believes that its ordinary shares will be eligible for trading on the OTC Bulletin Board, subject to the filing of a Form 211 by a market maker.

For more information on NexGen Biofuels, visit http://www.nexgenbiofuels.net

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of HealthCare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Form 8-K filed on January 7, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: HealthCare Technologies Ltd.

CONTACT: Eran Rotem CFO

+972-3-9277232-3


'/>"/>
SOURCE HealthCare Technologies Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
2. Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
5. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
6. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
8. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
11. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):